Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GATE-101
- Development stage
- Discontinued
- Lead developer
- Syndeio Biosciences
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
GATE-101 is a small molecule drug developed as an antagonist of metabotropic glutamate receptor 2 (mGluR2) and metabotropic glutamate receptor 3 (mGluR3). Its mechanism of action involves blocking these receptors, which are implicated in the modulation of neurotransmission in the central nervous system. The drug was primarily investigated for use in nervous system diseases, specifically major depressive disorder and idiopathic hypersomnia. Development was led by Gate Neurosciences. Clinical development reached Phase 1 trials, but the program has since been discontinued[1][2][3][4].
02
Targets
GRM2 (mGluR2)GRM3 (mGluR3)
Beyond the preview
Go deeper on GATE-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GATE-101.